GB201604458D0 - Peptides and combination of peptides for use in immunotherapy against cancers - Google Patents

Peptides and combination of peptides for use in immunotherapy against cancers

Info

Publication number
GB201604458D0
GB201604458D0 GBGB1604458.8A GB201604458A GB201604458D0 GB 201604458 D0 GB201604458 D0 GB 201604458D0 GB 201604458 A GB201604458 A GB 201604458A GB 201604458 D0 GB201604458 D0 GB 201604458D0
Authority
GB
United Kingdom
Prior art keywords
peptides
combination
immunotherapy against
against cancers
cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1604458.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to GBGB1604458.8A priority Critical patent/GB201604458D0/en
Publication of GB201604458D0 publication Critical patent/GB201604458D0/en
Priority to ES17710904T priority patent/ES2965011T3/es
Priority to CA3016410A priority patent/CA3016410A1/en
Priority to EP17710904.8A priority patent/EP3430027B1/en
Priority to KR1020227043762A priority patent/KR20230004914A/ko
Priority to NZ746979A priority patent/NZ746979A/en
Priority to SG10202006119TA priority patent/SG10202006119TA/en
Priority to PE2018001795A priority patent/PE20181824A1/es
Priority to PCT/EP2017/056049 priority patent/WO2017157972A1/en
Priority to AU2017235364A priority patent/AU2017235364B2/en
Priority to FIEP17710904.8T priority patent/FI3430027T3/fi
Priority to PL17710904.8T priority patent/PL3430027T3/pl
Priority to MX2018011215A priority patent/MX2018011215A/es
Priority to CR20180491A priority patent/CR20180491A/es
Priority to MA43719A priority patent/MA43719B1/fr
Priority to SG11201806905UA priority patent/SG11201806905UA/en
Priority to JP2018547374A priority patent/JP2019515650A/ja
Priority to DK17710904.8T priority patent/DK3430027T5/da
Priority to EA201891701A priority patent/EA201891701A1/ru
Priority to HRP20231570TT priority patent/HRP20231570T1/hr
Priority to KR1020257027081A priority patent/KR20250127181A/ko
Priority to BR112018017022A priority patent/BR112018017022A2/pt
Priority to PH1/2018/501865A priority patent/PH12018501865B1/en
Priority to UAA201808859A priority patent/UA128576C2/uk
Priority to HUE17710904A priority patent/HUE064592T2/hu
Priority to MA43327A priority patent/MA43327A1/fr
Priority to RS20231154A priority patent/RS64907B1/sr
Priority to CN201780017499.9A priority patent/CN108779149A/zh
Priority to LTEPPCT/EP2017/056049T priority patent/LT3430027T/lt
Priority to KR1020187026097A priority patent/KR20180121530A/ko
Priority to MYPI2018703090A priority patent/MY198565A/en
Priority to SI201731451T priority patent/SI3430027T1/sl
Priority to EP22201204.9A priority patent/EP4180450A1/en
Priority to MDE20190100T priority patent/MD3430027T2/ro
Priority to PT177109048T priority patent/PT3430027T/pt
Priority to US15/460,396 priority patent/US20170296641A1/en
Priority to CL2018002591A priority patent/CL2018002591A1/es
Priority to IL261785A priority patent/IL261785A/en
Priority to CONC2018/0010009A priority patent/CO2018010009A2/es
Priority to US16/681,472 priority patent/US20200085930A1/en
Priority to AU2022202307A priority patent/AU2022202307B2/en
Priority to AU2022287621A priority patent/AU2022287621B2/en
Priority to JP2023003167A priority patent/JP2023055722A/ja
Priority to CL2023001346A priority patent/CL2023001346A1/es
Priority to US18/490,581 priority patent/US12168044B2/en
Priority to US18/533,733 priority patent/US20240100137A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/39—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by a specific adjuvant, e.g. cytokines or CpG
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
GBGB1604458.8A 2016-03-16 2016-03-16 Peptides and combination of peptides for use in immunotherapy against cancers Ceased GB201604458D0 (en)

Priority Applications (46)

Application Number Priority Date Filing Date Title
GBGB1604458.8A GB201604458D0 (en) 2016-03-16 2016-03-16 Peptides and combination of peptides for use in immunotherapy against cancers
MA43327A MA43327A1 (fr) 2016-03-16 2017-03-15 Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du poumon non à petites cellules et d'autres cancers
PH1/2018/501865A PH12018501865B1 (en) 2016-03-16 2017-03-15 Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
UAA201808859A UA128576C2 (uk) 2016-03-16 2017-03-15 Пептиди та комбінації пептидів для застосування для імунотерапії недрібноклітинного раку легень та інших видів раку
EP17710904.8A EP3430027B1 (en) 2016-03-16 2017-03-15 Peptide for use in immunotherapy against non-small cell lung cancer and small cell lung cancer
KR1020227043762A KR20230004914A (ko) 2016-03-16 2017-03-15 비소세포 폐암 및 기타 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합
NZ746979A NZ746979A (en) 2016-03-16 2017-03-15 Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
SG10202006119TA SG10202006119TA (en) 2016-03-16 2017-03-15 Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
PE2018001795A PE20181824A1 (es) 2016-03-16 2017-03-15 Peptidos y combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pulmon amicrocitico y otros tipos de cancer
PCT/EP2017/056049 WO2017157972A1 (en) 2016-03-16 2017-03-15 Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
AU2017235364A AU2017235364B2 (en) 2016-03-16 2017-03-15 Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
FIEP17710904.8T FI3430027T3 (fi) 2016-03-16 2017-03-15 Peptidi käytettäväksi ei-pienisoluisen keuhkosyövän ja pienisoluisen keuhkosyövän hoidossa
PL17710904.8T PL3430027T3 (pl) 2016-03-16 2017-03-15 Peptyd do zastosowania w immunoterapii przeciw niedrobnokomórkowemu rakowi płuc oraz drobnokomórkowemu rakowi płuc
MX2018011215A MX2018011215A (es) 2016-03-16 2017-03-15 Peptidos y combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pulmon amicrocitico y otros tipos de cancer.
CR20180491A CR20180491A (es) 2016-03-16 2017-03-15 Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón amicrocítico y otros tipos de cáncer
MA43719A MA43719B1 (fr) 2016-03-16 2017-03-15 Peptide à utiliser en immunothérapie contre le cancer du poumon non à petites cellules et le cancer du poumon à petites cellules
SG11201806905UA SG11201806905UA (en) 2016-03-16 2017-03-15 Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
CA3016410A CA3016410A1 (en) 2016-03-16 2017-03-15 Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
DK17710904.8T DK3430027T5 (da) 2016-03-16 2017-03-15 Peptid til anvendelse ved immunterapi mod ikke-småcellet lungecancer og småcellet lungecancer
EA201891701A EA201891701A1 (ru) 2016-03-16 2017-03-15 Пептиды и комбинации пептидов для применения в иммунотерапии немелкоклеточного рака легких и других видов рака
HRP20231570TT HRP20231570T1 (hr) 2016-03-16 2017-03-15 Peptid za uporabu u imunoterapiji protiv nesitnostaničnog raka pluća i sitnostaničnog raka pluća
KR1020257027081A KR20250127181A (ko) 2016-03-16 2017-03-15 비소세포 폐암 및 기타 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합
BR112018017022A BR112018017022A2 (pt) 2016-03-16 2017-03-15 peptídeos e combinações de peptídeos para uso em imunoterapia contra câncer de pulmão de células não pequenas e outros cânceres
ES17710904T ES2965011T3 (es) 2016-03-16 2017-03-15 Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón amicrocítico y otros tipos de cáncer
HUE17710904A HUE064592T2 (hu) 2016-03-16 2017-03-15 Peptid nem-kissejtes tüdõrák és kissejtes tüdõrák elleni immunterápiában történõ alkalmazásra
JP2018547374A JP2019515650A (ja) 2016-03-16 2017-03-15 非小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ
PT177109048T PT3430027T (pt) 2016-03-16 2017-03-15 Péptido para utilização em imunoterapia contra cancro pulmonar de células não pequenas e cancro pulmonar de células pequenas
RS20231154A RS64907B1 (sr) 2016-03-16 2017-03-15 Peptid za upotrebu u imunoterapiji protiv nesitnoćelijskog kancera pluća i sitnoćelijskog kancera pluća
CN201780017499.9A CN108779149A (zh) 2016-03-16 2017-03-15 用于非小细胞肺癌和其他癌症免疫治疗的肽和肽组合物
LTEPPCT/EP2017/056049T LT3430027T (lt) 2016-03-16 2017-03-15 Peptidas, skirtas panaudoti imunoterapijoje prieš nesmulkialąstelinį plaučių vėžį ir smulkialąstelinį plaučių vėžį
KR1020187026097A KR20180121530A (ko) 2016-03-16 2017-03-15 비소세포 폐암 및 기타 암에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합
MYPI2018703090A MY198565A (en) 2016-03-16 2017-03-15 Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
SI201731451T SI3430027T1 (sl) 2016-03-16 2017-03-15 Peptid za uporabo v imunoterapiji proti nedrobnoceličnemu pljučnemu raku in drobnoceličnemu pljučnemu raku
EP22201204.9A EP4180450A1 (en) 2016-03-16 2017-03-15 Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
MDE20190100T MD3430027T2 (ro) 2016-03-16 2017-03-15 Peptide pentru utilizare în imunoterapia împotriva cancerului pulmonar nemicrocelular și a cancerului pulmonar microcelular
US15/460,396 US20170296641A1 (en) 2016-03-16 2017-03-16 Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
CL2018002591A CL2018002591A1 (es) 2016-03-16 2018-09-11 Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón amicrocítico y otros tipos de cáncer
IL261785A IL261785A (en) 2016-03-16 2018-09-15 Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
CONC2018/0010009A CO2018010009A2 (es) 2016-03-16 2018-09-21 Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón amicrocítico y otros tipos de cáncer
US16/681,472 US20200085930A1 (en) 2016-03-16 2019-11-12 Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
AU2022202307A AU2022202307B2 (en) 2016-03-16 2022-04-06 Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
AU2022287621A AU2022287621B2 (en) 2016-03-16 2022-12-15 Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
JP2023003167A JP2023055722A (ja) 2016-03-16 2023-01-12 非小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ
CL2023001346A CL2023001346A1 (es) 2016-03-16 2023-05-10 Uso de péptidos en inmunoterapia contra cáncer de pulmón amicrocítico y otros.
US18/490,581 US12168044B2 (en) 2016-03-16 2023-10-19 Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
US18/533,733 US20240100137A1 (en) 2016-03-16 2023-12-08 Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1604458.8A GB201604458D0 (en) 2016-03-16 2016-03-16 Peptides and combination of peptides for use in immunotherapy against cancers

Publications (1)

Publication Number Publication Date
GB201604458D0 true GB201604458D0 (en) 2016-04-27

Family

ID=55952389

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1604458.8A Ceased GB201604458D0 (en) 2016-03-16 2016-03-16 Peptides and combination of peptides for use in immunotherapy against cancers

Country Status (34)

Country Link
US (4) US20170296641A1 (enExample)
EP (2) EP4180450A1 (enExample)
JP (2) JP2019515650A (enExample)
KR (3) KR20230004914A (enExample)
CN (1) CN108779149A (enExample)
AU (3) AU2017235364B2 (enExample)
BR (1) BR112018017022A2 (enExample)
CA (1) CA3016410A1 (enExample)
CL (2) CL2018002591A1 (enExample)
CO (1) CO2018010009A2 (enExample)
CR (1) CR20180491A (enExample)
DK (1) DK3430027T5 (enExample)
EA (1) EA201891701A1 (enExample)
ES (1) ES2965011T3 (enExample)
FI (1) FI3430027T3 (enExample)
GB (1) GB201604458D0 (enExample)
HR (1) HRP20231570T1 (enExample)
HU (1) HUE064592T2 (enExample)
IL (1) IL261785A (enExample)
LT (1) LT3430027T (enExample)
MA (2) MA43327A1 (enExample)
MD (1) MD3430027T2 (enExample)
MX (1) MX2018011215A (enExample)
MY (1) MY198565A (enExample)
NZ (1) NZ746979A (enExample)
PE (1) PE20181824A1 (enExample)
PH (1) PH12018501865B1 (enExample)
PL (1) PL3430027T3 (enExample)
PT (1) PT3430027T (enExample)
RS (1) RS64907B1 (enExample)
SG (2) SG10202006119TA (enExample)
SI (1) SI3430027T1 (enExample)
UA (1) UA128576C2 (enExample)
WO (1) WO2017157972A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2968802T3 (es) * 2016-03-16 2024-05-14 Immatics Biotechnologies Gmbh Células T transfectadas y receptores de células T para su uso en inmunoterapia contra el cáncer
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP3539562A1 (en) 2018-03-12 2019-09-18 Eberhard Karls Universität Tübingen Medizinische Fakultät Immunotherapeutic peptides
DE102018108612A1 (de) * 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
EP3902560A1 (en) * 2018-12-28 2021-11-03 F. Hoffmann-La Roche AG A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
MA56036A (fr) 2019-05-27 2022-04-06 Immatics Us Inc Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive
KR20220018006A (ko) 2019-06-06 2022-02-14 이매틱스 바이오테크놀로지스 게엠베하 서열 유사 펩티드를 사용하는 계수기 선택에 의한 분류
MX2022000896A (es) * 2019-07-24 2022-02-14 Regeneron Pharma Receptores de antigenos quimericos con especificidad por mage-a4 y usos de los mismos.
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
EP3827840A1 (en) * 2019-11-29 2021-06-02 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Teipp peptide variant and uses thereof
CR20230295A (es) 2020-12-31 2023-07-27 Immatics Us Inc Polipéptidos cd8, composiciones y métodos de uso de estos
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
CN113896781B (zh) * 2021-03-24 2025-02-25 深圳市新靶向生物科技有限公司 一种与肺癌驱动基因突变相关的抗原肽及其应用
CN113087801B (zh) * 2021-04-07 2022-07-05 深圳市核子基因科技有限公司 一种用核酸和抗体联合检测肺癌的试剂盒
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
CN114230636B (zh) * 2021-11-12 2023-04-25 四川大学 一类多肽及其应用以及含该类多肽的药物
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
IL316515A (en) 2022-04-28 2024-12-01 Immatics Us Inc Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use
WO2023212691A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF
WO2023215825A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
CN115785208B (zh) * 2022-06-10 2024-07-12 河北博海生物工程开发有限公司 肺癌特异性分子靶标01及其用途
CN115785207B (zh) * 2022-06-10 2024-08-30 河北博海生物工程开发有限公司 肺癌特异性分子靶标02及其用途
CN115894575B (zh) * 2022-08-10 2024-11-19 河南大学 一种由非经典三层笼状簇构筑的多金属氧酸盐材料及其制备方法与应用
WO2024077601A1 (en) * 2022-10-14 2024-04-18 Guangdong Tcrcure Biopharma Technology Co., Ltd. Peptide vaccines against glioma and uses thereof
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2025233432A1 (en) * 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Use and dosage of an antigen-binding protein comprising a tcr specific for an hla-a*02 restricted peptide

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179338A (en) 1977-09-19 1979-12-18 Gordon Maurice R Microbiological medium suitable for sterilization by ionizing radiation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
EP0669836B1 (en) 1992-11-13 1996-07-03 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
CA2156725A1 (en) 1993-02-22 1994-09-01 Warren S. Pear Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6805861B2 (en) 1996-01-17 2004-10-19 Imperial College Innovations Limited Immunotherapy using cytotoxic T lymphocytes (CTL)
WO2000052163A1 (en) 1999-03-02 2000-09-08 Ludwig Institute For Cancer Research Cloning of cdna of mage's 5, 8, 9 and 11 and their uses in diagnosis of cancer
EP2336775A3 (en) 1999-12-06 2013-03-20 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
CA2393730A1 (en) * 1999-12-13 2001-06-14 Epimmune Inc. Hla class i a2 tumor associated antigen peptides and vaccine compositions
JP4900884B2 (ja) * 2000-07-31 2012-03-21 株式会社グリーンペプタイド 腫瘍抗原
AU2002257647A1 (en) 2001-03-09 2002-09-24 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
CA2481304A1 (en) 2002-03-27 2003-10-09 Patrick Hwu Method for treating cancer in humans
DE10225139A1 (de) 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
ES2327229T3 (es) 2002-11-09 2009-10-27 Immunocore Ltd. Presentacion del receptor de linfocitos t.
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
US7807392B1 (en) 2003-09-15 2010-10-05 Celera Corporation Lung disease targets and uses thereof
WO2005076009A2 (en) 2004-01-28 2005-08-18 Immatics Biotechnologies Gmbh Method for identifying and quantifying of tumour-associated peptides
US20090075832A1 (en) * 2005-02-24 2009-03-19 Cemines, Inc Compositions and Methods for Classifying Biological Samples
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
ATE461215T1 (de) 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
US8003770B2 (en) 2005-09-13 2011-08-23 Mie University T-cell receptor and nucleic acid encoding the receptor
WO2008053573A1 (fr) 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remède pour néoplasme malin
ES2553207T3 (es) 2007-07-27 2015-12-07 Immatics Biotechnologies Gmbh Nuevo epítopo inmunogénico para inmunoterapia
ES2672769T3 (es) 2007-08-29 2018-06-18 Sanofi Anticuerpos anti-CXCR5 humanizados, derivados de los mismos y sus usos
CA3139492C (en) 2007-09-26 2024-04-30 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
CN102083979B (zh) 2008-05-09 2015-01-07 新加坡科技研究局 Hbv表位反应性外源t细胞受体(tcr)及其用途
PL2119726T5 (pl) 2008-05-14 2018-04-30 Immatics Biotechnologies Gmbh Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu
TW201008574A (en) * 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
GB0917094D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
US10464987B2 (en) 2009-10-06 2019-11-05 Abbvie Inc. Human single-chain T cell receptors
US20130011496A1 (en) * 2009-11-25 2013-01-10 Ludwig Institute For Cancer Research Ltd. Cancer testis antigens as biomarkers in non-small cell lung cancer
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
WO2011146473A1 (en) 2010-05-17 2011-11-24 Duke University Methods of treatment using ex vivo expansion of cord blood t cells
CN101870725B (zh) * 2010-06-29 2012-06-27 郑州大学 Mage-4抗肿瘤ctl表位肽及其应用
US9586997B2 (en) 2010-09-20 2017-03-07 Biontech Cell & Gene Therapies Gmbh Antigen-specific T cell receptors and T cell epitopes
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CN103957930A (zh) * 2011-08-31 2014-07-30 国立大学法人三重大学 癌症治疗用疫苗制剂
WO2013057596A1 (en) 2011-10-21 2013-04-25 Atena Srl Anatomic cushion accumulator for thermal treatment with heat or cold
EP2660250B1 (en) 2012-05-02 2018-11-14 Deutsches Rheuma-Forschungszentrum Berlin Tcr transgenic mouse model for immune disease
MX2015000979A (es) 2012-07-27 2015-11-23 Univ Illinois Ingenieria de receptores de celulas t.
HUE048014T2 (hu) 2012-09-14 2020-05-28 Us Health MHC Class II-korlátozott MAGE-A3-at felismerõ T-sejt receptorok
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
GB2508414A (en) 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
CA2906566C (en) 2013-03-14 2024-09-10 Macrogenics Inc Immunoreactive bispecific molecules at immune effector cells expressing an activation receptor
AU2014236769B2 (en) 2013-03-15 2018-09-27 Amgen Inc. Heterodimeric bispecific antibodies
US9937207B2 (en) 2013-03-21 2018-04-10 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using talens
JP6549564B2 (ja) 2013-06-26 2019-07-24 グアンドン シャンスエ ライフ サイエンス， リミテッド． 高安定性のｔ細胞受容体およびその製法と使用
TWI636065B (zh) 2013-08-05 2018-09-21 伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
JP6164759B2 (ja) 2013-11-21 2017-07-19 Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 Ｔ細胞受容体およびｂ細胞受容体レパトアの解析システムならびにその治療および診断への利用
HUE050156T2 (hu) 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
US10202640B2 (en) 2014-05-07 2019-02-12 The Board Of Trustees Of The Leland Stanford Junior University Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
WO2015172843A1 (en) * 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Methods and kits for the diagnosis of cancer
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
JP6599450B2 (ja) * 2014-10-02 2019-10-30 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
EP3215164A1 (en) 2014-11-03 2017-09-13 Immures S.r.l. T cell receptors
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
CN114230667A (zh) 2015-01-23 2022-03-25 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
EP3067366A1 (en) 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201506642D0 (en) 2015-04-20 2015-06-03 Ucl Business Plc T cell receptor
PT3298033T (pt) 2015-05-18 2020-09-22 Tcr2 Therapeutics Inc Composições e utilizações médicas para reprogramação de tcr utilizando proteínas de fusão
EP3095792A1 (en) 2015-05-19 2016-11-23 Klinikum rechts der Isar der Technischen Universität München T cell receptor with specificity for myeloperoxidase peptide and uses thereof
CN105219719A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活卵巢癌特异性免疫反应的试剂盒
CN105219714A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活肺癌特异性免疫反应的试剂盒
RU2022103665A (ru) 2015-10-23 2022-03-05 Еурека Терапьютикс, Инк. Химерные конструкции антитело/t-клеточный рецептор и их применения
GB201522592D0 (en) 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
GB201604492D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
ES2968802T3 (es) 2016-03-16 2024-05-14 Immatics Biotechnologies Gmbh Células T transfectadas y receptores de células T para su uso en inmunoterapia contra el cáncer
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
US11325961B2 (en) 2016-08-05 2022-05-10 Tohoku University Natural killer cell function enhancer
GB201617716D0 (en) 2016-10-19 2016-11-30 Ucl Business Plc Cell
GB201617714D0 (en) 2016-10-19 2016-11-30 Ucl Business Plc T Cell receptor
DE102016121899A1 (de) 2016-11-15 2018-05-17 Immatics Biotechnologies Gmbh Verfahren zur Herstellung von elektrokompetenten Hefezellen und Verfahren zur Verwendung dieser Zellen
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
US10988754B2 (en) 2017-07-04 2021-04-27 Cure Vac AG Nucleic acid molecules
CR20200013A (es) 2017-07-14 2020-03-11 Immatics Biotechnologies Gmbh Molécula de polipéptido con especificidad dual mejorada
CA3072816A1 (en) 2017-08-18 2019-02-21 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared antigens
EP3679065A4 (en) 2017-09-06 2021-05-19 California Institute of Technology SIGNALING AND ANTIGEN-PRESENTING BIFUNCTIONAL RECEPTORS (SABR)
WO2019091478A1 (en) 2017-11-10 2019-05-16 Chineo Medical Technology Co., Ltd. Modified immune cells and uses thereof
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
TWI837109B (zh) 2017-12-28 2024-04-01 美商磨石生物公司 靶向共有抗原之抗原結合蛋白
DE102018100967B4 (de) 2018-01-17 2019-08-14 Immatics US, Inc. Verfahren zur feststellung der wirksamkeit von viralen vektoren
JPWO2019151392A1 (ja) 2018-01-31 2021-02-04 国立大学法人東北大学 抗原特異的ｍｈｃ発現調節法
KR20200119840A (ko) 2018-02-09 2020-10-20 이매틱스 유에스 인코포레이티드 T 세포의 제조 방법
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
ES2935702T3 (es) 2018-04-11 2023-03-09 Enterome S A Péptidos antigénicos para la prevención y el tratamiento del cáncer
CA3100253A1 (en) 2018-05-14 2019-11-21 Immunocore Limited Bifunctional binding polypeptides
JP2021526365A (ja) 2018-05-18 2021-10-07 チルドレンズ ナショナル メディカル センターＣｈｉｌｄｒｅｎ’Ｓ Ｎａｔｉｏｎａｌ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 改善された標的化ｔ細胞療法
JP7554119B2 (ja) 2018-05-23 2024-09-19 グリットストーン バイオ インコーポレイテッド 共有抗原
EP3802614A1 (en) 2018-06-04 2021-04-14 Apo-T B.V. Methods and means for attracting immune effector cells to tumor cells
GB201819540D0 (en) 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
CA3126611A1 (en) 2019-01-17 2020-07-23 Immunocore Limited Formulations of soluble t cell receptor(tcr) and single chain fragment variable (scfv) bispecific proteins
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
MX2021013588A (es) 2019-05-08 2022-02-11 Medigene Immunotherapies Gmbh Células t genomodificadas.
AU2020279224B2 (en) 2019-05-21 2024-12-05 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
WO2020257288A2 (en) 2019-06-18 2020-12-24 Regeneron Pharmaceuticals, Inc. Mage-a4 t cell receptors and methods of use thereof
GB201911286D0 (en) 2019-08-07 2019-09-18 Ucl Business Plc Method
CN114729305A (zh) 2019-10-17 2022-07-08 苏州丹罗医药有限公司 用于免疫治疗的嵌合抗原受体、制备方法及其应用
JP2023531385A (ja) 2020-06-04 2023-07-24 セーフシール－システムズ セルフシール容器
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides

Also Published As

Publication number Publication date
ES2965011T3 (es) 2024-04-10
EP3430027B1 (en) 2023-09-13
CL2018002591A1 (es) 2018-11-05
CN108779149A (zh) 2018-11-09
MA43719A (fr) 2018-11-28
SG10202006119TA (en) 2020-08-28
JP2023055722A (ja) 2023-04-18
BR112018017022A2 (pt) 2019-02-05
MA43327A1 (fr) 2018-12-31
JP2019515650A (ja) 2019-06-13
US20240123044A1 (en) 2024-04-18
AU2017235364B2 (en) 2022-01-06
AU2022287621B2 (en) 2024-08-15
IL261785A (en) 2018-10-31
RS64907B1 (sr) 2023-12-29
US12168044B2 (en) 2024-12-17
PH12018501865A1 (en) 2019-07-15
HRP20231570T1 (hr) 2024-03-15
PL3430027T3 (pl) 2024-03-04
CL2023001346A1 (es) 2023-10-06
HUE064592T2 (hu) 2024-03-28
KR20250127181A (ko) 2025-08-26
AU2022202307A1 (en) 2022-04-28
EP4180450A1 (en) 2023-05-17
LT3430027T (lt) 2023-11-27
PT3430027T (pt) 2023-12-15
MY198565A (en) 2023-09-05
UA128576C2 (uk) 2024-08-21
SG11201806905UA (en) 2018-09-27
EP3430027A1 (en) 2019-01-23
MA43719B1 (fr) 2023-11-30
WO2017157972A1 (en) 2017-09-21
US20200085930A1 (en) 2020-03-19
DK3430027T5 (da) 2024-09-23
US20170296641A1 (en) 2017-10-19
CO2018010009A2 (es) 2018-09-28
EA201891701A1 (ru) 2019-02-28
AU2022202307B2 (en) 2022-09-15
NZ746979A (en) 2025-03-28
PE20181824A1 (es) 2018-11-29
FI3430027T3 (fi) 2023-11-29
KR20230004914A (ko) 2023-01-06
PH12018501865B1 (en) 2024-01-24
MD3430027T2 (ro) 2024-03-31
DK3430027T3 (da) 2023-12-04
MX2018011215A (es) 2018-11-22
AU2017235364A1 (en) 2018-10-25
SI3430027T1 (sl) 2024-01-31
CR20180491A (es) 2019-01-09
CA3016410A1 (en) 2017-09-21
AU2022287621A1 (en) 2023-02-02
US20240100137A1 (en) 2024-03-28
KR20180121530A (ko) 2018-11-07

Similar Documents

Publication Publication Date Title
GB201604458D0 (en) Peptides and combination of peptides for use in immunotherapy against cancers
SG10202101368WA (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
SG10202007962RA (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers
IL259304A (en) New peptides and a combination of peptides for use in immunotherapy against cll and other types of cancer
GB201511792D0 (en) Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
ZA201800513B (en) Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
SG10202001485UA (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors
IL256189A (en) New peptides and combinations of peptides used in immunotherapy against ovarian cancer and other types of cancer
ZA201801036B (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SG11201706155XA (en) Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
SG10202001665QA (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG10202005950XA (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
ZA201707810B (en) Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
GB201604490D0 (en) Peptides combination of peptides for use in immunotherapy against cancers
IL258609A (en) New peptides and a combination of peptides for use in immunotherapy against several types of cancer
SG10202100326SA (en) Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
IL254081B (en) New peptides and a combination of peptides for immunotherapeutic use against pancreatic cancer and other types of cancer
ZA201805512B (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers
SG10202110335PA (en) Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)